Try a new search

Format these results:

Searched for:



Total Results:


Rheumatic diseases

Chapter by: Lee, Sicy H; Rosenthal, Pamela B; Abramson, Steven B
in: Medical aspects of disability for the rehabilitation professionals by Moroz, Alex; Flanagan, Steven R; Zaretsky, Herbert H [Eds]
[New York] : Springer Publishing Company, 2017
pp. ?-?
ISBN: 9780826133199
CID: 2558932

Increased interleukin-1beta gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis

Attur, Mukundan; Belitskaya-Levy, Ilana; Oh, Cheongeun; Krasnokutsky, Svetlana; Greenberg, Jeffrey; Samuels, Jonathan; Smiles, Stephen; Lee, Sicy; Patel, Jyoti; Al-Mussawir, Hayf; McDaniel, Gary; Kraus, Virginia Byers; Abramson, Steven B
OBJECTIVE: To evaluate whether gene expression profiles could serve as biomarkers of symptomatic knee osteoarthritis (OA) by examining gene expression profiles in peripheral blood leukocytes (PBLs) from patients with OA compared with those from non-OA controls, and to determine whether candidate genomic biomarkers (PBL expression of inflammatory genes) predict an increased risk of disease progression in patients with symptomatic radiographic knee OA. METHODS: Three independent cohorts of patients with knee OA and non-OA control subjects were studied. Two cohorts (a learning cohort and a validation cohort) were recruited at New York University Hospital for Joint Diseases (NYUHJD), and 1 cohort (a validation cohort) was recruited at Duke University Medical Center. PBL gene expression was assessed using Affymetrix microarray and was confirmed by quantitative polymerase chain reaction (qPCR). Radiographic progression at 2 years was assessed in 86 patients. RESULTS: We identified 173 genes that were significantly up-regulated or down-regulated (>/=1.5-fold change) in OA PBLs, at a false discovery rate of 5%. Cluster analysis revealed 2 distinct subgroups among the patients with OA: those in whom the expression of interleukin-1beta (IL-1beta) was increased >/=2-fold compared with controls, and those in whom the expression of IL-1beta was comparable with that in controls. Overexpression of IL-1beta in these OA subclasses was validated using qPCR in all 3 cohorts. Patients with the inflammatory 'IL-1beta signature' had higher pain scores and decreased function and were at higher risk of radiographic progression of OA. CONCLUSION: PBLs from patients with symptomatic knee OA display a characteristic transcriptome profile. Moreover, increased expression of IL-1beta identifies a subset of patients with OA who have increased pain and are at higher risk of radiographic progression of OA
PMID: 21717421
ISSN: 1529-0131
CID: 134740

Rheumatic diseases

Chapter by: Lee, Sicy H; Abramson, Steven B
in: Medical aspects of disability : a handbook for the rehabilitation professional by Flanagan, Steven R; Zaretsky, Herbert H; Moroz, Alex [Eds]
New York : Springer, c2011
pp. 511-530
ISBN: 0826127843
CID: 5795

The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk

Greenberg, J D; Fisher, M C; Kremer, J; Chang, H; Rosenstein, E D; Kishimoto, M; Lee, S; Yazici, Y; Kavanaugh, A; Abramson, S B
OBJECTIVE:To examine effects of the COX-2 inhibitor market withdrawals on NSAID utilization among patients at increased risk of gastrointestinal (GI) and cardiovascular (CV) toxicities. METHODS:A prospective cohort study was conducted using patients enrolled in the Consortium of Rheumatology Researchers of North America (CORRONA) Registry. The study population included rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients prescribed NSAIDs by rheumatologists from 1/1/2003 to 12/31/2005. Three cohorts were defined based on calendar year. The primary outcome assessed whether or not an NSAID gastroprotective strategy was prescribed. Secondary outcomes included rates of COX-2 inhibitor utilization and gastroprotective co-therapy utilization, stratified by the presence of cardiac and GI risk factors. RESULTS:NSAID gastroprotection utilization decreased from 65.1% in 2003 to 47.7% (p<0.001) in 2005. COX-2 inhibitor use decreased from 55.1% to 29.2% (p<0.001), whereas nonselective NSAIDs (nsNSAIDs) use increased from 50.2% to 73.9% (p=<0.01). Among patients with two or more risk factors for NSAID related GI bleeding, gastroprotection decreased from 74.4% in 2003 to 60.9% (p<0.01). For patients with two or more CV risk factors from 2003 to 2005, COX-2 inhibitor utilization decreased significantly, whereas nsNSAID utilization increased significantly.CONCLUSIONS:The COX-2 inhibitor withdrawals resulted in a rapid decline in NSAID gastroprotection prescribed by participating U.S. rheumatologists despite the availability of other gastroprotective options. Channeling toward nsNSAID use was widespread, including among patients at increased CV risk. Longer term follow-up is required to determine the clinical significance of these changes in NSAID prescribing, particularly for NSAID-related GI and CV-related toxicities
PMID: 19604430
ISSN: 0392-856x
CID: 100676

Peripheral blood leukocytes (PBL) gene expression profiles as biomarkers in patients with human knee osteciarthritis (OA) [Meeting Abstract]

Krasnokutsky, S; Attur, M; Belitskaya-Levy, I; Patel, J; Al-Mussawir, H; Smiles, S; Lee, S; Kraus, V; Kong, SY; McDaniel, G; Abramson, SB
ISSN: 0004-3591
CID: 70764

NSAID and COXIB prescribing by rheumatologist for patients with gastrointestinal (GI) and cardiovascular (CV) risk in 2004-2005 [Meeting Abstract]

Greenberg, JD; Abramson, SB; Lee, S; Rosenstein, E; Reed, G; Hinkle, K; Kavanaugh, A; Kremer, J
ISSN: 0004-3591
CID: 59296

Rheumatic Diseases

Chapter by: Lee, Sicy H; Abramson, Steven B
in: Medical aspects of disability : a handbook for the rehabilitation professional by Zaretsky, Herbert H [Eds]
New York, NY, US: Springer Publishing Co, 2005
pp. 538-610
ISBN: 0826179738
CID: 4091

One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women

Friedlander, A L; Butterfield, G E; Moynihan, S; Grillo, J; Pollack, M; Holloway, L; Friedman, L; Yesavage, J; Matthias, D; Lee, S; Marcus, R; Hoffman, A R
The activity of the hypothalamic-GH-insulin-like growth factor I (hypothalamic-GH-IGF-I) axis declines with age, and some of the catabolic changes of aging have been attributed to the somatopause. The purpose of this investigation was to determine the impact of 1 yr of IGF-I hormone replacement therapy on body composition, bone density, and psychological parameters in healthy, nonobese, postmenopausal women over 60 yr of age. Subjects (n = 16, 70.6 +/- 2.0 yr, 71.8 +/- 2.8 kg) were randomly assigned to either the self-injection IGF-I (15 microg/kg twice daily) or placebo group and were studied at baseline, at 6 months, and at 1 yr of treatment. There were no significant differences between the IGF-I and placebo groups in any of the measured variables at baseline. Fasting blood IGF-I levels were significantly elevated above baseline values (65.6 +/- 11.9 ng/mL) at 6 months (330.0 +/- 52.8) and 12 months (297.7 +/- 40.8) in the IGF-I treated group but did not change in the placebo subjects. Circulating levels of IGF-binding protein-1 and -3 were unaffected by the IGF-I treatment. Bone mineral density of the forearm, lumbar spine, hip, and whole body [as measured by dual-energy x-ray absorptiometry (DXA)] did not change in either group. Similarly, there was no difference in DXA-measured lean mass, fat mass, or percent body fat throughout the treatment intervention. Muscle strength values (grip, bench press, leg press), blood lipid parameters (cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides), and measures of postmeal glucose disposal were not altered by IGF-I treatment, although postmeal insulin levels were lower in the IGF-I subjects at 12 months. IGF-I did not affect bone turnover markers (osteocalcin and type I collagen N-teleopeptide), but subjects who were taking estrogen had significantly lower turnover markers than subjects who were not on estrogen at baseline, 6 months, and 12 months. Finally, the psychological measures of mood and memory were also not altered by the intervention. Despite the initial intent to recruit additional subjects, the study was discontinued after 16 subjects completed the protocol, because the preliminary analyses above indicated that no changes were occurring in any outcome variables, regardless of treatment regimen. Therefore, we conclude that 1 yr of IGF-I treatment, at a dose sufficient to elevate circulating IGF-I to young normal values, is not an effective means to alter body composition or blood parameters nor improve bone density, strength, mood, or memory in older women
PMID: 11297574
ISSN: 0021-972x
CID: 127785

Vaccination of rheumatoid arthritis (RA) patients with DR4/1-peptide [Meeting Abstract]

StClair, EW; Cohen, SB; Fleischmann, RM; Lee, S; Moreland, L; Olsen, NJ; Pratt, PW; Yocum, DE; Winkelhake, J; Holcenberg, J; Shulman, MG
ISSN: 0004-3591
CID: 53183

Treatment of rheumatoid arthritis (RA) with thalidomide [Meeting Abstract]

Lee, S; Klausner, J; Oliver, S; Kaplan, G; McCullagh, E
ISSN: 0004-3591
CID: 52789